LCL521 dihydrochloride is a dual inhibitor of acid ceramidase (ACDase) and lysosomal acid sphingomyelinase (ASMase). By targeting these lysosomal enzymes, LCL521 dihydrochloride modulates sphingolipid metabolism, with potential applications in cancer and metabolic disorder research.

LCL521 dihydrochloride is a potent cellular ACDase inhibitor at a concentration of 1 µM. At a higher concentration (10 µM), LCL521 dihydrochloride additionally exerts a reducing effect on the α-form of ACDase. Specifically, in MCF7 cells, LCL521 dihydrochloride (10 µM) induces a time-dependent decrease in the α-ACDase form, which is observable within 1 to 5 hours.[1]